LEXEO THERAPEUTICS INC (LXEO)
Health Care · Genetic medicine / gene therapy for rare cardiovascular diseases · NASDAQ
Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich ataxia cardiomyopathy.
What LEXEO THERAPEUTICS INC does
Lexeo Therapeutics is a clinical-stage genetic medicine company developing therapeutic candidates to treat cardiovascular diseases by targeting underlying genetic causes. The company's lead program, LX2006, is being evaluated in Phase 1/2 trials for Friedreich ataxia cardiomyopathy, with additional programs targeting cardiomyopathy associated with PKP2 mutations and arrhythmogenic cardiomyopathy. The company focuses on applying pioneering genetic medicine science to reshape treatment of cardiovascular diseases with high unmet medical need.
Themes: ["Genetic medicine / gene therapy","Cardiovascular disease treatment","Rare genetic cardiomyopathies","Clinical-stage therapeutics","Friedreich ataxia"]
Fundamentals
- Price$5.05 as of 2026-07-09 close
- Market cap$415M as of 2026-07-10
- 1-year return+18.9% as of 2026-07-09 close
- Net margin-11991.8% as of 2026-07-10
- ROE-47.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.33 as of 2026-07-10
Key risks (from latest filing)
["Early clinical stage with only Phase 1/2 data; pivotal study results and regulatory approval remain uncertain","Reliance on third-party manufacturing partners to comply with significant manufacturing regulations and achieve scalability for commercial viability","Small patient populations for rare genetic cardiovascular diseases may limit market opportunity and patient enrollment in trials"]
Competitors & peers
- Solid Biosciences
- Reata Pharmaceuticals
- Sarepta Therapeutics
- Modern Water
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.